Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The CPRX news feed on Stock Titan aggregates company announcements, financial updates, scientific disclosures, and investor conference appearances drawn from Catalyst’s own public communications and regulatory filings.
Readers can find earnings and financial result announcements, where Catalyst reports product revenue contributions from FIRDAPSE, AGAMREE, and FYCOMPA, along with commentary on operating performance and business outlook. These releases often discuss factors such as organic growth in Lambert-Eaton myasthenic syndrome markets, demand in Duchenne muscular dystrophy centers of excellence, and the impact of generic competition on specific products.
The news stream also features corporate and strategic updates, including authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, and developments in clinical practice guidelines that reference conditions and therapies linked to the company’s portfolio. In addition, Catalyst regularly announces participation in major healthcare and investor conferences, providing insight into how management presents the story behind CPRX to the investment community.
For those following the scientific and patient-focused side of the business, the news includes conference presentations and advocacy initiatives, such as real-world analyses in Duchenne muscular dystrophy, research on Lambert-Eaton myasthenic syndrome, and programs like the Catalyst Advocacy Scholars Summit with academic partners. Investors, analysts, and patients can use this page to monitor how Catalyst’s rare disease strategy, clinical activities, and capital allocation decisions evolve over time. Bookmark this CPRX news page for a centralized view of the company’s key public announcements.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will present multiple real‑world poster analyses of vamorolone in Duchenne muscular dystrophy and sponsor an MDA Industry Forum with Santhera at the 2026 MDA Clinical & Scientific Conference in Orlando.
Key events: three poster presentations on March 8, 2026 (6:00–8:00 PM ET) and a sponsored symposium on March 10, 2026 (12:00–1:30 PM ET) in the Hilton Orlando Key Largo Room.
Catalyst Pharmaceuticals (Nasdaq: CPRX) reported record full year 2025 total revenues of $589.0 million, a 19.8% increase, and Q4 2025 revenues of $152.6 million. GAAP net income was $214.3 million; cash and cash equivalents were $709.2 million at year-end.
The company provided 2026 guidance of $615 million to $645 million in total revenues, with FIRDAPSE expected at $435M–$450M and AGAMREE at $140M–$150M. Catalyst announced a $200 million share repurchase program and completed substantial buybacks in 2025.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:30 PM ET.
Management led by President and CEO Rich Daly will webcast the presentation; the webcast is available via the company investor website and a replay will be accessible for at least 30 days.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release fourth quarter and full-year 2025 financial results after market close on February 25, 2026. Management will host a conference call and webcast on February 26, 2026 at 8:30 AM ET to discuss results and provide a business update.
Dial-in numbers are provided for US/Canada and international callers, and the webcast will be available in the Investors section at www.catalystpharma.com. A replay will remain on the website for at least 30 days following the event.
Catalyst Pharmaceuticals (Nasdaq: CPRX) and The University of Notre Dame announced the inaugural Catalyst Advocacy Scholars Summit (CASS), a week-long immersive program for 12 students enrolled in Notre Dame’s Patient Advocacy Minor.
The summit runs January 5–9, 2026 in Coral Gables, Fla., and is designed to educate students on patient advocacy and biopharmaceutical operations while giving Catalyst access to student perspectives on its programs. Catalyst said it aims to attract talent to the industry and increase patient focus across scientific degree programs.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced that President and CEO Rich Daly and other management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:45pm PST. The presentation will be webcast from the company’s investor website and a replay will be available for at least 30 days.
The company described itself as a commercial-stage biopharmaceutical focused on in-licensing, developing, and commercializing therapies for rare and difficult-to-treat diseases.
Catalyst Pharmaceuticals (Nasdaq: CPRX) said President and CEO Rich Daly and other executives will participate in the Bank of America CNS Therapeutics Virtual Conference on Monday, December 8, 2025 at 12:35pm ET.
The session will be available via webcast on the company investor website at www.catalystpharma.com, and a replay will be accessible for at least 30 days after the presentation.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced on November 19, 2025 that it ranked #304 on the 2025 Deloitte Technology Fast 500™. The ranking is based on percentage revenue growth from fiscal year 2021 to 2024, during which Catalyst reported 249% revenue growth. The company attributes the growth to portfolio momentum and commercial execution and noted this is the second consecutive year it earned a Fast 500 placement, improving from #452 in 2024. The announcement frames the recognition as evidence of sustained commercial progress and operational discipline while reaffirming commitment to patients and long-term growth.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced that President & CEO Rich Daly and other management will participate in Citi’s 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 2025.
The company’s presentation is scheduled for 1:00 PM ET. A live webcast will be available via the Investors section at www.catalystpharma.com, and a replay will be available for at least 30 days after the presentation.
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 2025 total revenues of $148.4M, driven by FIRDAPSE, AGAMREE and FYCOMPA, and raised full‑year 2025 total revenue guidance to $565M–$585M.
Key metrics: FIRDAPSE Q3 net revenue $92.2M (+16.2% YoY), AGAMREE Q3 net revenue $32.4M (+115.2% YoY), FYCOMPA Q3 net revenue $23.8M (‑25.8% YoY). GAAP net income was $52.8M and non‑GAAP net income was $86.1M for the quarter. Cash and cash equivalents were $689.9M as of September 30, 2025.
The company announced a $200M share repurchase program (Oct 1, 2025–Dec 31, 2026) and noted a pending patent trial with a tentative date in March 2026.